Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.31 |
| ▸ | HTR3B | O95264 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11557169 | 0.93 | MEN1 (0.57) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL14129761 | 0.93 | KDM4E (0.43) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Methylpiperazine SCHEMBL8376387 | 0.92 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Methylpiperazine SCHEMBL4903056 | 0.92 | MEN1 (0.41) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL14129555 | 0.91 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Methylpiperazine SCHEMBL1813508 | 0.90 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Methylpiperazine SCHEMBL27384494 | 0.88 | — | — | |
| SCHEMBL14571215 | 0.87 | MEN1 (0.38) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Methylpiperazine SCHEMBL6524500 | 0.87 | ALDH1A1 (0.38) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Methylpiperazine SCHEMBL1363 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | MEN1 1354/4885KMT2A 523/4885KDM4E 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.